Literature DB >> 12202461

Endocrinological disorders and celiac disease.

Pekka Collin1, Katri Kaukinen, Matti Välimäki, Jorma Salmi.   

Abstract

Celiac disease is a permanent intolerance to dietary gluten. Its well known features are abdominal symptoms, malabsorption of nutrients, and small-bowel mucosal inflammation with villous atrophy, which recover on a gluten-free diet. Diagnosis is challenging in that patients often suffer from subtle, if any, symptoms. The risk of clinically silent celiac disease is increased in various autoimmune conditions. The endocrinologist, especially, should maintain high suspicion and alertness to celiac disease, which is to be found in 2-5% of patients with insulin-dependent diabetes mellitus or autoimmune thyroid disease. Patients with multiple endocrine disorders, Addison's disease, alopecia, or hypophysitis may also have concomitant celiac disease. Similar heredity and proneness to autoimmune conditions are considered to be explanations for these associations. A gluten-free diet is essential to prevent celiac complications such as anemia, osteoporosis, and infertility. The diet may also be beneficial in the treatment of the underlying endocrinological disease; prolonged gluten exposure may even contribute to the development of autoimmune diseases. The diagnosis of celiac disease requires endoscopic biopsy, but serological screening with antiendomysial and antitissue transglutaminase antibody assays is an easy method for preliminary case finding. Celiac disease will be increasingly detected provided the close association with autoimmune endocrinological diseases is recognized.

Entities:  

Mesh:

Year:  2002        PMID: 12202461     DOI: 10.1210/er.2001-0035

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  57 in total

1.  Celiac disease in Type 1 diabetic children and adults: IgA class transglutaminase autoantibodies as the best screening marker.

Authors:  A Meoro; I Eleno; J Sánchez; V Chinchilla; J A Caselles; A Payá; M Pérez-Mateo; A Picó
Journal:  J Endocrinol Invest       Date:  2005-10       Impact factor: 4.256

2.  Epidemiology of autoimmune diseases in Denmark.

Authors:  William W Eaton; Noel R Rose; Amanda Kalaydjian; Marianne G Pedersen; Preben Bo Mortensen
Journal:  J Autoimmun       Date:  2007-06-19       Impact factor: 7.094

3.  Suppression of HPA axis in adults taking inhaled corticosteroids.

Authors:  J R Greenfield; K Samaras
Journal:  Thorax       Date:  2006-03       Impact factor: 9.139

4.  Celiac disease in the Turkish population.

Authors:  Rengin Elsurer; Gonca Tatar; Halis Simsek; Yasemin H Balaban; Musa Aydinli; Cenk Sokmensuer
Journal:  Dig Dis Sci       Date:  2005-01       Impact factor: 3.199

5.  Celiac sprue: a unique autoimmune disorder.

Authors:  Shadi Rashtak; Eric V Marietta; Joseph A Murray
Journal:  Expert Rev Clin Immunol       Date:  2009-09       Impact factor: 4.473

Review 6.  Celiac disease and autoimmunity in the gut and elsewhere.

Authors:  Susan H Barton; Joseph A Murray
Journal:  Gastroenterol Clin North Am       Date:  2008-06       Impact factor: 3.806

Review 7.  Antibodies in celiac disease: implications beyond diagnostics.

Authors:  Sergio Caja; Markku Mäki; Katri Kaukinen; Katri Lindfors
Journal:  Cell Mol Immunol       Date:  2011-01-31       Impact factor: 11.530

8.  High prevalence of coeliac disease in siblings of children with type 1 diabetes.

Authors:  Zdenek Sumnik; Stanislava Kolouskova; Hana Malcova; Jan Vavrinec; Jitrenka Venhacova; Jan Lebl; Ondrej Cinek
Journal:  Eur J Pediatr       Date:  2004-10-07       Impact factor: 3.183

9.  Prevalence of celiac disease in Shiraz, southern Iran.

Authors:  Mehdi Saberi-Firouzi; Gholamhossein R Omrani; Marzieh Nejabat; Davood Mehrabani; Farnaz Khademolhosseini
Journal:  Saudi J Gastroenterol       Date:  2008-07       Impact factor: 2.485

10.  An unusual cause of adult onset cerebellar ataxia with hypogonadism.

Authors:  Ramshekhar N Menon; Nirav Sanghani; Mahendra Javali; Neeraj Jain; Arun B Shah
Journal:  Ann Indian Acad Neurol       Date:  2009-01       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.